未知生产厂商
Burixafor (GPC-100) is an investigational small-molecule CXCR4 antagonist being developed as a rapid-acting hematopoietic stem cell mobilization agent for patients with blood cancers, including multiple myeloma.
Burixafor (GPC-100) is an investigational small-molecule CXCR4 antagonist being developed as a rapid-acting hematopoietic stem cell mobilization agent for patients with blood cancers, including multiple myeloma.
Burixafor (GPC-100) is a small-molecule CXCR4 antagonist that targets the CXCR4 and ADRB2 cell membrane protein complex, mobilizing hematopoietic stem cells and immune cells into the peripheral blood of patients with blood cancers.
共 1 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
